This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
21 Jun 2012

CellCentric & ZoBio Enter into Partnership to Develop Lead Compounds against Epigenetic Drug Targets

ZoBio will use its proprietary TINS technology to screen its fragment library against targets nominated by CellCentric.

ZoBio and CellCentric are working together to discover lead compounds against CellCentric’s portfolio of epigenetic therapeutic drug targets.

 

ZoBio will use its proprietary TINS technology to screen its fragment library against targets nominated by CellCentric. Hit to lead and lead optimisation activities will be further supported by ZoBio’s biophysical and medicinal chemistry research services.

 

Dr. Gregg Siegal, Chief Scientific Officer at ZoBio said “We are clearly happy that CellCentric has chosen ZoBio as a partner in this challenging project. Epigenetics is an exciting, yet challenging, field. We feel that our unique combination of biophysical and biochemical approaches yields significant advantages in developing small molecule inhibitors of these targets

Related News